Insider Buying: Telix Pharmaceuticals (NASDAQ:TLX) CEO Buys 33,435 Shares of Stock

Telix Pharmaceuticals Limited (NASDAQ:TLX) CEO Christian Behrenbruch acquired 33,435 shares of the stock in a transaction that occurred on Wednesday, April 29th. The stock was acquired at an average cost of $14.87 per share, for a total transaction of $497,178.45. Following the completion of the purchase, the chief executive officer owned 20,742,935 shares in the company, valued at $308,447,443.45. The trade was a 0.16% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Christian Behrenbruch also recently made the following trade(s):

• On Tuesday, April 28th, Christian Behrenbruch acquired 34,500 shares of Telix Pharmaceuticals stock. The stock was acquired at an average cost of $14.48 per share, for a total transaction of $499,560.00.

Telix Pharmaceuticals Stock Up 0.6%

NASDAQ TLX traded up $0.07 during trading hours on Wednesday, reaching $11.11. The company’s stock had a trading volume of 87,368 shares, compared to its average volume of 208,018. Telix Pharmaceuticals Limited has a fifty-two week low of $6.28 and a fifty-two week high of $18.49. The company’s 50-day moving average is $9.10 and its two-hundred day moving average is $8.77. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.43 and a quick ratio of 1.27.

Telix Pharmaceuticals (NASDAQ:TLX) last issued its quarterly earnings data on Friday, February 20th. The company reported ($0.01) EPS for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.06). The company had revenue of $206.72 million for the quarter, compared to analysts’ expectations of $421.50 million. As a group, research analysts forecast that Telix Pharmaceuticals Limited will post 0.09 EPS for the current year.

Wall Street Analyst Weigh In

TLX has been the topic of a number of recent research reports. Weiss Ratings restated a “sell (d)” rating on shares of Telix Pharmaceuticals in a report on Monday, April 20th. Wall Street Zen upgraded shares of Telix Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, April 11th. Citigroup upped their target price on shares of Telix Pharmaceuticals from $22.00 to $22.50 and gave the company a “buy” rating in a report on Tuesday, February 24th. Royal Bank Of Canada upgraded shares of Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a report on Monday, January 19th. Finally, Wedbush restated an “outperform” rating and issued a $22.00 target price on shares of Telix Pharmaceuticals in a report on Monday, April 13th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $21.13.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of TLX. Rhumbline Advisers lifted its holdings in shares of Telix Pharmaceuticals by 117.3% during the 3rd quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock worth $25,000 after acquiring an additional 1,392 shares during the period. XTX Topco Ltd purchased a new position in shares of Telix Pharmaceuticals during the 4th quarter worth about $89,000. OLD Mission Capital LLC acquired a new stake in Telix Pharmaceuticals during the 4th quarter worth approximately $111,000. Vident Advisory LLC acquired a new stake in Telix Pharmaceuticals during the 4th quarter worth approximately $204,000. Finally, IHT Wealth Management LLC acquired a new stake in Telix Pharmaceuticals during the 2nd quarter worth approximately $213,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.